Detalhe da pesquisa
1.
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med
; 384(20): 1885-1898, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33725432
2.
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
Antimicrob Agents Chemother
; 67(10): e0068323, 2023 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37768317
3.
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Lancet Infect Dis
; 23(3): 295-306, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36273491
4.
Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
Vaccine
; 41(23): 3486-3492, 2023 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37149443
5.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
Lancet HIV
; 8(9): e568-e580, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34416193